Precision Oncology Market Report 2026

The precision oncology market size has grown rapidly in recent years. It will grow from $106.21 billion in 2025 to $117.67 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to limited availability of genomic sequencing technologies, reliance on conventional chemotherapy, increasing cancer prevalence globally, early adoption of immunotherapy, growing research in molecular oncology.

The precision oncology market size is expected to see rapid growth in the next few years. It will grow to $175.38 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to development of next-generation sequencing platforms, increasing integration of bioinformatics and AI in oncology, rising adoption of liquid biopsy and molecular imaging, expansion of personalized treatment options, growth of research collaborations between hospitals and pharmaceutical companies. Major trends in the forecast period include expansion of targeted cancer therapies based on molecular profiling, increasing adoption of liquid biopsy and non-invasive diagnostic methods, growth in biomarker-based testing for personalized treatment plans, rising integration of immunotherapy with genomic sequencing, enhanced focus on rare and hard-to-treat cancer types.

The heightened recognition and pivot to personalized therapies is set to boost the precision oncology market ahead. Personalized therapies adapt to a patient's genetics, markers, and disease traits for sharper efficacy and fewer downsides. Their growth flows from genomic tech strides that spot mutation drivers precisely, unlocking targeted fixes. Precision oncology propels personalized therapies via tumor genomic and molecular scans to customize cancer care to individual profiles. For example, in February 2023, GOV.UK announced the Health and Social Care Secretary's MoU with BioNTech SE to push cancer vaccine work in England, targeting 10,000 personalized doses for UK patients by 2030. Thus, the rising awareness and shift to personalized therapies is fueling the precision oncology market.

Top companies in the precision oncology market are pioneering methods like molecular tumor boards to guide bespoke decisions by blending genomic data with clinical insights. A molecular tumor board is an expert team reviewing intricate genomic and molecular results to shape patient-specific cancer plans based on tumor specifics. For instance, in December 2024, Aster DM Healthcare Ltd., a UAE healthcare network, launched a precision oncology clinic within three tailored cancer programs, harnessing data-led, gene-centric tactics. It crafts individualized therapies from tumor genetics, yielding pinpoint accuracy, better results, and slimmer side effects. This aligns treatments to unique cancer molecules, lifting survival, curbing harm, and enriching life quality.

In March 2024, Bayer AG, a Germany-based pharma leader, allied with Aignostics GmbH to elevate precision oncology using the latter's AI pathology and patient data for smarter cancer drug hunts. Aignostics GmbH is a Germany AI firm supplying tools honed for precision oncology.

Major companies operating in the precision oncology market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., AstraZeneca plc., Novartis AG, Amgen Inc., Agilent Technologies Inc., Illumina Inc., Qiagen N.V., Exact Sciences Corporation, NeoGenomics Laboratories Inc., Myriad Genetics Inc., Invitae Corporation, Caris Life Sciences, Foundation Medicine Inc., NanoString Technologies Inc., Personalis Inc., Strata Oncology Inc.

North America was the largest region in the precision oncology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the precision oncology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the precision oncology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the precision oncology market by increasing costs of imported sequencing equipment, reagents, and biologic therapeutics. Segments such as genomic sequencing platforms, biomarker-based tests, and immunotherapy products are most affected, with North America, Europe, and Asia-Pacific regions reliant on imports facing higher operational costs. While tariffs have slowed supply chains and raised treatment costs, they have also encouraged local production, investment in domestic research infrastructure, and innovation in cost-effective precision oncology solutions.

The precision oncology market research report is one of a series of new reports that provides precision oncology market statistics, including precision oncology industry global market size, regional shares, competitors with a precision oncology market share, detailed precision oncology market segments, market trends and opportunities, and any further data you may need to thrive in the precision oncology industry. This precision oncology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Precision oncology is a medical approach that customizes cancer treatment based on the unique characteristics of each patient. This strategy utilizes molecular and genetic profiling of tumors to identify specific mutations, biomarkers, or pathways driving cancer progression, enabling clinicians to choose targeted therapies that are more effective and less toxic compared with conventional treatments.

The main types of precision oncology include genomic sequencing and immunotherapy. Genomic sequencing involves determining the complete DNA sequence of an organism’s genome at a given time. Product offerings in this area include genetic tests, biomarker-based tests, and targeted therapeutics, applied in treating various cancers such as breast, lung, colorectal, prostate, skin, stomach, and others. Supporting technologies include next-generation sequencing, bioinformatics, molecular imaging, and liquid biopsy. The primary end users are hospitals, research laboratories, pharmaceutical companies, and diagnostic centers.

The precision oncology market consists of revenues earned by entities by providing services such as genomic and molecular profiling services, companion diagnostics services, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The precision oncology market also includes sales of genomic and molecular diagnostic equipment, immune checkpoint inhibitors, and bioinformatics and decision support tools. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.